Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

46.88
-1.9500-3.99%
Post-market: 46.880.00000.00%18:52 EDT
Volume:881.42K
Turnover:42.17M
Market Cap:2.98B
PE:-20.35
High:49.81
Open:49.25
Low:46.73
Close:48.83
Loading ...

Moonlake Immunotherapeutics Held Annual General Meeting of Shareholders

Reuters
·
Yesterday

Post-Bell | U.S. Stocks End Higher; Nvidia Gains 3%; Dollar General Jumps 16%; CoreWeave Surges 25%

Tiger Newspress
·
04 Jun

MoonLake Immunotherap Price Target Maintained With a $67.00/Share by RBC Capital

Dow Jones
·
03 Jun

MoonLake Immunotherapeutics Up Nearly 17%, on Pace for Largest Percent Increase Since June 2023 -- Data Talk

Dow Jones
·
03 Jun

Shares of MoonLake Immunotherapeutics Surge 17% After FT Reports Merck Held Talks to Buy Co for Over $3 Bln

THOMSON REUTERS
·
03 Jun

RBC Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
03 Jun

MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating

TIPRANKS
·
03 Jun

Deals of the day-Mergers and acquisitions

Reuters
·
03 Jun

MoonLake Soars 23.5% as Merck Holds Talks to Buy the Biotech Company for over $3 Billion

Reuters
·
03 Jun

PRESS DIGEST- Financial Times - June 3

Reuters
·
03 Jun

24H|MoonLake Surges 17%; Credo Jumps 13%; Applied Digital Gains Another 4% After Soaring 48%

Tiger Newspress
·
03 Jun

BRIEF-Merck Held Talks To Buy Swiss Biotech Moonlake For More Than $3 Bln- FT

Reuters
·
03 Jun

Wolfe upgrades MoonLake Immunotherapeutics ahead of sonelokimab data

TIPRANKS
·
19 May

Stock Track | MoonLake Immunotherapeutics Soars 5.58% Following Wolfe Research Upgrade to Outperform

Stock Track
·
19 May

Wolfe Research Upgrades MoonLake Immunotherapeutics to Outperform From Peer Perform

MT Newswires Live
·
19 May

MoonLake Immunotherap Raised to Outperform From Peer Perform by Wolfe Research

Dow Jones
·
19 May

MoonLake upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
19 May

Wedbush Adjusts Price Target on MoonLake Immunotherapeutics to $80 From $78, Maintains Outperform Rating

MT Newswires Live
·
13 May

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

Dow Jones
·
13 May

Swiss stocks - Factors to watch on May 13

Reuters
·
13 May